bookmaker definition

bookmaker definition Subsplash Acquires Pulpit AI, an Innovative Platform Leveraging AI to Help Streamline Content Creation & Boost Sermon Engagement for Churches

Tulsi Gabbard, Trump’s pick for intel chief, faces questions on Capitol Hill amid Syria falloutBasketball NBA Market Overview and Leading Players: Kevin Durant, Nikola Jokic, Zion Williamson, Khris Middleton, Joel Embiid, Russell Westbrook, Paul George, Jayson Tatum 12-08-2024 09:17 PM CET | Sports Press release from: STATS N DATA The Basketball NBA Market has emerged as a dynamic and influential sector within the global sports industry, capturing the attention of millions of fans, players, and stakeholders worldwide. This market encompasses a broad range of activities and products, including professional and amateur basketball engagements, merchandise sales, broadcast rights, and sponsorship deals. The relevance of this market extends beyond the basketball court, as it influences cultural trends, community engagement, and economic growth in various regions. Recent months have seen significant developments in the Basketball NBA Market, largely driven by technological advancements and strategic collaborations. The integration of digital platforms has transformed how fans engage with the sport, allowing for real-time interactions and enhanced viewing experiences. The rise of streaming services and social media platforms has created new revenue streams and marketing opportunities, enabling teams and players to connect with their audiences like never before. Additionally, partnerships between teams and technology companies are reshaping the landscape, providing innovative solutions that enhance player performance and fan engagement. You can access a sample PDF report here: https://www.statsndata.org/download-sample.php?id=376957 Key Growth Drivers and Trends Several critical factors are influencing the demand within the Basketball NBA Market. Sustainability has become a cornerstone of consumer expectations, prompting organizations to prioritize eco-friendly practices in their operations, from merchandise production to arena management. Digitization is another key driver, enhancing accessibility and engagement through mobile apps, virtual reality experiences, and social media interactions. Increased consumer awareness has led to a more informed fan base that demands transparency and corporate responsibility from teams and brands. Trends such as AI integration are revolutionizing the way players train and strategize. Advanced analytics and machine learning algorithms are being utilized to assess player performance, optimize training regimens, and inform coaching decisions. Moreover, product customization is gaining traction, with fans increasingly seeking personalized merchandise that reflects their individual preferences. Emerging technologies, such as virtual reality and augmented reality, are also shaping the market's future, offering immersive experiences that deepen fan engagement and broaden the appeal of the sport. Market Segmentation The Basketball NBA Market can be segmented into several categories, allowing for a comprehensive understanding of its dynamics. - By Type: - Professional basketball players - Amateur basketball players - College basketball players - By Application: - NBA players - International basketball players - Street basketball players - Recreational basketball players - By Product Preferences: - Basketball apparel and footwear - Basketball equipment (balls, hoops, training aids) - Basketball accessories (bags, protective gear) - By Revenue Streams: - Ticket sales - Merchandise sales - Broadcast rights and advertising revenue This segmentation reveals the multifaceted nature of the Basketball NBA Market, highlighting diverse opportunities for growth and innovation across various audience segments. Get 30% Discount On Full Report: https://www.statsndata.org/ask-for-discount.php?id=376957 Competitive Landscape The competitive landscape of the Basketball NBA Market is shaped by numerous influential players who are at the forefront of driving trends and innovation. Notable figures include: - Kevin Durant: Known for his exceptional scoring ability, Durant has also made significant contributions off the court, including philanthropic efforts and brand partnerships that resonate with fans. - Nikola Jokic: As a dominant force in the NBA, Jokic's playing style has garnered attention, while his unique personality and marketability have expanded his influence beyond basketball. - Zion Williamson: The young star has quickly become a household name, leveraging his social media presence to engage with fans and promote basketball culture. - Khris Middleton: Middleton's clutch performances have not only secured championships but also solidified his role as a leader in community initiatives. - Joel Embiid: Embiid's dynamic playing style and charismatic personality have made him a fan favorite, while his advocacy for social issues has set a powerful example in the sport. - Russell Westbrook: Known for his relentless energy, Westbrook has made significant strides in fashion and lifestyle branding, connecting with a diverse audience. - Paul George: George's influence extends to community outreach and advocacy, demonstrating how athletes can leverage their platforms for social good. - Jayson Tatum: Tatum's rise in the league has been accompanied by a keen focus on personal branding and fan engagement, making him a prominent figure among younger audiences. - Stephen Curry: As one of the most recognizable athletes globally, Curry has transformed the way basketball is played and marketed, through both his on-court success and off-court ventures. - Bradley Beal: Beal's contributions to the game and community initiatives underscore the importance of player engagement in the NBA landscape. - Bam Adebayo: Adebayo has gained recognition for his defensive prowess and leadership, while also engaging fans through social media and community service. - Devin Booker: Booker's impact on the game is complemented by his efforts in promoting mental health awareness among athletes. - Giannis Antetokounmpo: The "Greek Freak" has not only dominated on the court but has also become a global ambassador for the sport. - Anthony Davis: Davis's stature in the league and his commitment to health and wellness initiatives position him as a key player in the market. - Damian Lillard: Lillard's dual career as a musician and athlete allows him to connect with fans on multiple levels. - Donovan Mitchell: Mitchell's dynamic playing style and community engagement efforts highlight the importance of athlete representation. - Luka Doncic: The young star's global appeal has drawn international attention to the NBA, emphasizing the league's growth beyond American borders. - LeBron James: A transformative figure in sports, LeBron has leveraged his platform for social justice, making him one of the most influential athletes in history. - Kyrie Irving: Irving's impact on the game is matched by his commitment to social causes and unique personal brand. - Jimmy Butler: Butler's journey in the league and his emphasis on mental health have resonated with fans, showcasing the human side of athletes. - Karl-Anthony Towns: Towns's advocacy for mental health awareness and community engagement demonstrates the potential for athletes to drive positive change. - James Harden: Harden's style of play and marketability have made him a central figure in basketball culture. - Trae Young: Young's rise in the league has been accompanied by his innovative style and fan engagement strategies. - Kawhi Leonard: Leonard's quiet demeanor and on-court excellence have made him a respected figure in the sport. - Chris Paul: A veteran leader, Paul's contributions extend beyond the court, advocating for players' rights and community initiatives. Each of these athletes plays a pivotal role in shaping the market, whether through product innovations, brand partnerships, or community engagement efforts. Opportunities and Challenges The Basketball NBA Market presents numerous opportunities for growth, particularly in untapped regions and emerging demographics. Expanding into international markets offers a significant avenue for revenue growth, as basketball continues to gain popularity worldwide. Additionally, evolving consumer preferences toward sustainable products and experiences create a favorable environment for brands to innovate and adapt. However, the market is not without challenges. Regulatory constraints can impact operational flexibility, complicating expansion efforts. Operational inefficiencies, particularly in supply chains and logistics, may hinder growth potential. Moreover, talent shortages in coaching and player development can impede the progress of emerging teams. Addressing these challenges requires strategic partnerships, investment in training programs, and a commitment to fostering a culture of innovation within organizations. Technological Advancements Technological advancements are reshaping the Basketball NBA Market in unprecedented ways. Artificial Intelligence (AI) is revolutionizing player analytics, providing coaches with deep insights into performance metrics and game strategies. AI-driven tools are enabling teams to optimize training regimens, enhance player health monitoring, and even personalize fan experiences. Virtual reality (VR) and augmented reality (AR) are also making waves in the market. These technologies offer immersive experiences for fans, allowing them to engage with the sport in new ways, whether through virtual arenas or interactive training sessions with their favorite players. Internet of Things (IoT) systems are enhancing arena experiences, providing real-time data and analytics that improve overall fan engagement and operational efficiency. Research Methodology and Insights The insights presented in this report are derived from a comprehensive research methodology employed by STATS N DATA. This approach combines top-down and bottom-up methodologies to ensure accurate market assessments. Primary research includes interviews with industry experts, stakeholders, and market participants, while secondary research leverages existing data and reports to validate findings. Triangulation techniques further enhance the reliability of the insights, providing a robust foundation for understanding the dynamics of the Basketball NBA Market. In conclusion, the Basketball NBA Market stands at a pivotal moment, characterized by growth opportunities, technological advancements, and evolving consumer preferences. The interplay of these factors will shape the future of the sport, creating an exciting landscape for players, teams, and fans alike. As this market continues to evolve, STATS N DATA remains committed to delivering accurate, insightful analyses that empower stakeholders to navigate the complexities of the Basketball NBA Market effectively. For customization requests, please visit: https://www.statsndata.org/request-customization.php?id=376957 https://www.statsndata.org/report/basketball-nba-market-376957 Get more information about recently published reports by STATS N DATA below: You can then follow this with links or a list of the specific reports The Ultimate Guide to the Best Protein Water: Trends, Benefits, and Choosing the Right Option: https://www.statsndata.org/blog/172/the-ultimate-guide-to-the-best-protein-water-trends-benefits-and-choosing-the-right-option The Evolution of Protein Bar Manufacturing in the USA: Top Trends, Industry Insights, and Practical Tips: https://www.statsndata.org/blog/178/the-evolution-of-protein-bar-manufacturing-in-the-usa-top-trends-industry-insights-and-practical-tips Top 10 Trends Transforming the Swimwear Market: Key Insights and Strategic Tips: https://www.statsndata.org/blog/180/top-10-trends-transforming-the-swimwear-market-key-insights-and-strategic-tips John Jones Sales & Marketing Head | Stats N Data Phone: +1 (315) 642-4324 Email: sales@statsndata.org Website: www.statsndata.org STATS N DATA is a trusted provider of industry intelligence and market research, delivering actionable insights to businesses across diverse sectors. We specialize in helping organizations navigate complex markets with advanced analytics, detailed market segmentation, and strategic guidance. Our expertise spans industries including technology, healthcare, telecommunications, energy, food & beverages, and more. Committed to accuracy and innovation, we provide tailored reports that empower clients to make informed decisions, identify emerging opportunities, and achieve sustainable growth. Our team of skilled analysts leverages cutting-edge methodologies to ensure every report addresses the unique challenges of our clients. At STATS N DATA, we transform data into knowledge and insights into success. Partner with us to gain a competitive edge in today's fast-paced business environment. For more information, visit https://www.statsndata.org or contact us today at sales@statsndata.org This release was published on openPR.Be Among the First to Experience MEGA Revolution - World's First 70W Intelligent Desktop Engraving Machine

Where to watch Bayer Leverkusen vs. Inter, lineups, odds: Champions League live stream, pick, predictionGypsy-Rose Blanchard Is Ready to Tell Her Story — Then Leave It All Behind

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myelomaLeading NFL MVP candidate Josh Allen had the best fantasy performance by a quarterback ever in Week 14, logging an incredible six touchdowns (three through the air, three on the ground) en route to 51.88 fantasy points. Not only is Allen’s monster day the best of the fantasy era, if you applied fantasy scoring rules to earlier pro football contests, Allen still tops the charts. The second-best historical QB performance was over six decades ago, in 1961, when Houston Oiler George Blanda would have produced a 49.72-point game. Coincidentally, his teammate Billy Cannon had the best-ever fantasy performance by a player at any position (68 points) during the same season. Advertisement To better contextualize Allen’s accomplishment for the modern era, here are the best fantasy performances by quarterbacks since 2004. Rankings and statistics in this article are from Stathead. 5. Nick Foles , Philadelphia Eagles , Nov. 3, 2013 Nick Foles threw for seven — seven! — touchdown passes and 406 yards on 22-of-28 passing, supplementing 10 yards on the ground to lead the Eagles over the Raiders in 2013. In that 49-20 trouncing of Oakland , Foles tied the NFL record for passing touchdowns and told reporters, “A couple of people came up to me and said that I tied the record with seven touchdowns,” adding, “It’s a great honor. Hats off to our guys for doing a great job.” Along with Foles, George Blanda, Drew Brees, Adrian Burk, Joe Kapp, Sid Luckman, Peyton Manning and Y.A. Tittle still hold the single-game record for passing TDs. 4. Aaron Rodgers , Green Bay Packers , Oct. 2, 2011 During a 49-23 rout of the Broncos, Aaron Rodgers threw four touchdowns and ran for two more, completing 29 passes for 408 yards to the tune of a 134.5 passer rating. He rushed for another 36 yards. One interception (and sitting out the Packers’ final two drives) kept him out of third place on this list. The Denver Post’s Mike Klis likened Rodgers’ performance against the Broncos to playing “with a new toy.” He wrote, “Rodgers smiled and threw a touchdown pass. He smiled and ran for a touchdown. He smiled and smiled and smiled.” Greg Jennings (103 receiving yards, one TD) and Jordy Nelson (91 receiving yards, one TD) led Green Bay receivers in this historic (in the fantasy sense) game. What the 2024 New York Jets wouldn’t do for 2011 regular-season Aaron Rodgers. 3. Peyton Manning, Denver Broncos, Sept. 5, 2013 In another seven-passing-touchdown performance, Peyton Manning and the Broncos crushed the Ravens 49-27 on “Thursday Night Football.” Manning threw for 462 yards and had a passer rating of 141.1. While he didn’t throw an interception, he was unable to pad his stats on the ground — because Peyton Manning — posting negative two yards, . Advertisement The late Demaryius Thomas ended the game with 161 yards receiving and two touchdowns, while Julius Thomas also had over 100 yards receiving and two TDs. The latter Thomas spoke highly of his QB, according to ESPN : “He’s phenomenal. To continue to come out every year and put that kind of performance on for us, it’s amazing.” Manning made fantasy-quarterback history during his 15th season at 37 years old. 2. Michael Vick, Philadelphia Eagles, Nov. 15, 2010 The second Eagle on the list, Michael Vick had a career game against Washington , leading Philadelphia to a 59-28 win. In a game nicknamed “The Monday Night Massacre,” the under-center speedster rushed for 80 yards and two touchdowns and threw for 333 yards, adding another four touchdowns through the air. He was never intercepted and finished with a 150.7 passer rating. Vick’s first play of the game was an 88-yard touchdown pass to Philly great DeSean Jackson . He also played most of the contest (three quarters) without his signature visor due to rain. Ten years after the fact, Vick recalled the historic game and told The Athletic , “I could remember everything because I saw it clear. I didn’t see it behind the tint of a visor. I saw it in the right perspective. And I’m glad it happened.” 1. Josh Allen, Buffalo Bills , Dec. 8, 2024 Josh Allen tops this list but he is the only quarterback here who didn’t secure a win. After trailing 38-21 entering the fourth quarter, Buffalo lost 44-42 , partially due to the mishandling of timeouts and a lack of awareness on the final punt. Head coach Sean McDermott called a costly timeout late in the game, and rookie Brandon Codrington let the final punt drop to the 1-yard line as time expired. Allen’s 342 yards passing and 82 yards rushing, Khalil Shakir ’s 106 yards receiving with a touchdown, and Amari Cooper ’s 95 yards receiving weren’t enough. Advertisement But the Bills are still 10-3, have clinched the AFC East and are looking toward the playoffs. In Week 15, Buffalo will face the Detroit Lions in what could be a precursor to a potential Super Bowl matchup. The Bills’ final two games are against the New York Jets and New England Patriots — two bottom-of-the-barrel opponents who should hope they don’t have to face the Josh Allen of Week 14. And Allen is still most likely to be the 2024-25 MVP. For all the NFL/pop-culture fans out there, he also proposed to now-fiancé Hailee Steinfeld last month. All in all, Allen is having a career year, but I bet he wants this one back. (Photo of Josh Allen: Katelyn Mulcahy / Getty Images)Investors want to see ‘ambition’ from UK on climate change, Pinchbeck says

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 ( Abstract #493 ) and MajesTEC-4 ( Abstract #494 ) studies establish the potential of TECVAYLI ® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting. 1,2 Forty-nine patients with transplant-eligible NDMM were treated with TECVAYLI ® in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj), lenalidomide and dexamethasone (Tec-DRd) or DARZALEX FASPRO ® , bortezomib, lenalidomide and dexamethasone (Tec-DVRd) as induction therapy in the MajesTEC-5 study. 1 All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10 -5 ) and maintained through cycle 6. 1 "These data from the MajesTEC-5 study build on the growing body of evidence of TECVAYLI combinations that support the potential combinability of TECVAYLI with other effective therapies, demonstrating high rates of MRD-negative responses for evaluable patients with newly diagnosed multiple myeloma," said Rachel Kobos, M.D., Vice President, Oncology Research & Development, Johnson & Johnson Innovative Medicine. "At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're committed to exploring the full potential of our therapies to improve outcomes for patients." The safety profiles were manageable and consistent with individual safety profiles. 1 No treatment-emergent adverse events (TEAEs) led to study treatment discontinuation or death; cytokine release syndrome (CRS; Grade 1 or 2) occurred in 65 percent of patients. 1 No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). 1 Grade 3/4 TEAEs included lymphopenia (43 percent), neutropenia (57 percent) and infections (35 percent). 1 "There remains opportunity to achieve even deeper and more sustained outcomes for a broader patient population in the frontline setting," said Marc S. Raab , M.D., Heidelberg University Hospital, Germany .* "These data reinforce the potential of TECVAYLI when used in earlier lines and show that TECVAYLI can be leveraged to optimize existing standard regimens in combination." Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of TECVAYLI ® to be administered as a maintenance therapy following autologous stem cell transplant (ASCT). 2 MajesTEC-4 is the first study to present data on a B-cell maturation antigen (BCMA) bispecific as monotherapy or combination therapy after ASCT. 2 Low rates of non-hematologic Grade 3/4 TEAEs and discontinuation of treatment due to all TEAEs (5.3 percent) were observed. CRS events were all Grade 1/2, mostly occurring during step-up dosing, and ICANS was not observed. Neutropenia and infections were the most common Grade 3/4 TEAEs. 2 Grade 3/4 neutropenia at 6 months showed a decreased trend in cohorts 2 and 3 with less frequent TECVAYLI ® dosing (cohort 1: 94 percent, cohort 2: 63 percent, cohort 3: 47 percent). 2 A similar trend was observed for all-grade infections (cohort 1: 94 percent; cohort 2: 78 percent; cohort 3: 77 percent). 2 All evaluable patients in cohort 1 who underwent MRD assessment after 12 months of therapy were MRD negative, and 100 percent of evaluable patients assessed in cohorts 2 and 3 were also MRD negative at cycle 6. 2 Further analysis of combination therapies will be evaluated in the Phase 3 MajesTEC-7 study, which is currently enrolling. About MajesTEC-5 Study MajesTEC-5 ( NCT05695508 ) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with newly diagnosed transplant eligible multiple myeloma. 3 About MajesTEC-4 Study MajesTEC-4 ( NCT05243797 ) is an ongoing, multicenter, randomized, open-label, Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation. 4 About MajesTEC-7 Study MajesTEC-7 ( NCT05552222 ) is a Phase 3 randomized study comparing teclistamab in combination with daratumumab SC and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab SC and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy. 5 About TECVAYLI ® TECVAYLI ® (teclistamab-cqyv) received approval from the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. 6 The European Commission (EC) granted TECVAYLI ® conditional marketing authorization (CMA) in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023 , the EC granted the approval of a Type II variation application for TECVAYLI ® , providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI ® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In February 2024 , the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months. For more information, visit www.TECVAYLI.com . About DARZALEX FASPRO ® and DARZALEX ® DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible. It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX FASPRO ® is co-formulated with recombinant human hyaluronidase PH20, Halozyme's ENHANZE ® drug delivery technology. DARZALEX ® is the first CD38-directed antibody approved to treat multiple myeloma. DARZALEX ® -based regimens have been used in the treatment of more than 585,000 patients worldwide and more than 239,000 patients in the U.S. alone. In August 2012 , Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. For more information, visit https://www.darzalexhcp.com. About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 7 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors. 8 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease. 9 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease. 10 People living with multiple myeloma have a 5-year survival rate of 59.8 percent. 11 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections. 12,13 TECVAYLI ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL- ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI ® . Initiate treatment with TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI ® until CRS resolves or permanently discontinue based on severity. Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and serious and life- threatening reactions, can occur in patients receiving TECVAYLI ® . Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI ® until neurologic toxicity resolves or permanently discontinue based on severity. TECVAYLI ® is available only through a restricted program called the TECVAYLI ® and TALVEY ® Risk Evaluation and Mitigation Strategy (REMS). INDICATION AND USAGE TECVAYLI ® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). WARNINGS AND PRECAUTIONS Cytokine Release Syndrome - TECVAYLI ® can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI ® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients. Most patients experienced CRS following step-up dose 1 (42%), step-up dose 2 (35%), or the initial treatment dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI ® . The median time to onset of CRS was 2 (range: 1 to 6) days after the most recent dose with a median duration of 2 (range: 1 to 9) days. Clinical signs and symptoms of CRS included, but were not limited to, fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation). Initiate therapy according to TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Administer pretreatment medications to reduce risk of CRS and monitor patients following administration of TECVAYLI ® accordingly. At the first sign of CRS, immediately evaluate patient for hospitalization. Administer supportive care based on severity and consider further management per current practice guidelines. Withhold or permanently discontinue TECVAYLI ® based on severity. TECVAYLI ® is available only through a restricted program under a REMS. Neurologic Toxicity including ICANS - TECVAYLI ® can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI ® at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%). With longer follow-up, Grade 4 seizure and fatal Guillain-Barré syndrome (one patient each) occurred in patients who received TECVAYLI ® . In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI ® at the recommended dose. Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI ® . The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI ® based on severity per recommendations and consider further management per current practice guidelines. Due to the potential for neurologic toxicity, patients are at risk of depressed level of consciousness. Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI ® step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves. TECVAYLI ® is available only through a restricted program under a REMS. TECVAYLI ® and TALVEY ® REMS - TECVAYLI ® is available only through a restricted program under a REMS called the TECVAYLI ® and TALVEY ® REMS because of the risks of CRS and neurologic toxicity, including ICANS. Hepatotoxicity - TECVAYLI ® can cause hepatotoxicity, including fatalities. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, there was one fatal case of hepatic failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations in 0.6%. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Infections - TECVAYLI ® can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%. Monitor patients for signs and symptoms of infection prior to and during treatment with TECVAYLI ® and treat appropriately. Administer prophylactic antimicrobials according to guidelines. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Monitor immunoglobulin levels during treatment with TECVAYLI ® and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Neutropenia - TECVAYLI ® can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients. Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines. Monitor patients with neutropenia for signs of infection. Withhold TECVAYLI ® based on severity. Hypersensitivity and Other Administration Reactions - TECVAYLI ® can cause both systemic administration-related and local injection-site reactions. Systemic Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, 1.2% of patients experienced systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue. Local Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, injection-site reactions occurred in 35% of patients, with Grade 1 injection-site reactions in 30% and Grade 2 in 4.8%. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Embryo-Fetal Toxicity - Based on its mechanism of action, TECVAYLI ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TECVAYLI ® and for 5 months after the last dose. ADVERSE REACTIONS The most common adverse reactions (≥20%) were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets. Please read full Prescribing Information , including Boxed WARNING, for TECVAYLI ® . DARZALEX FASPRO ® INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DARZALEX FASPRO ® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation. WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO ® . Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO ® . Systemic Reactions In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO ® as monotherapy or in combination, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 0.7%, Grade 4: 0.1%). Systemic administration-related reactions occurred in 7% of patients with the first injection, 0.2% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 2.9 hours (range: 5 minutes to 3.5 days). Of the 165 systemic administration-related reactions that occurred in 93 patients, 144 (87%) occurred on the day of DARZALEX FASPRO ® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO ® . Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO ® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO ® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO ® . Local Reactions In this pooled safety population, injection-site reactions occurred in 7% of patients, including Grade 2 reactions in 0.8%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO ® . Monitor for local reactions and consider symptomatic management. Neutropenia Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO ® until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO ® , higher rates of Grade 3-4 neutropenia were observed. Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO ® until recovery of platelets. Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO ® can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO ® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO ® and for 3 months after the last dose. The combination of DARZALEX FASPRO ® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant women because lenalidomide, thalidomide, and pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide, or pomalidomide prescribing information on use during pregnancy. Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO ® . Type and screen patients prior to starting DARZALEX FASPRO ® . Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO ® -treated patients with IgG kappa myeloma protein. ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO ® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematology laboratory abnormalities (≥40%) with DARZALEX FASPRO ® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please click here to see the full Prescribing Information for DARZALEX FASPRO ® . About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com . Follow us at @JanssenUS and @JNJInnovMed . Janssen Research & Development, LLC and Janssen Biotech, Inc. are both Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TECVAYLI ® (teclistamab-cqyv ) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. * Marc S. Raab , M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. 1 Raab, Marc, S., et al, 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 2 Zamagni, Elena, et al., 494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 3 GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX). https://clinicaltrials.gov/study/NCT05695508 . Accessed November 2024 . 4 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4). https://clinicaltrials.gov/study/NCT05243797 . Accessed November 2024 . 5 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7). https://classic.clinicaltrials.gov/ct2/show/NCT05552222 . Accessed November 2024 . 6 U.S. FDA Approves TECVAYLI ® (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma . Accessed November 2024 . 7 Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-5672020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178 8 National Cancer Institute. Plasma Cell Neoplasms. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq . Accessed November 2024 . 9 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. https://www.cancercenter.com/cancer-types/multiple-myeloma . Accessed November 2024 . 10 American Cancer Society. Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html#:~:text=Multiple%20myeloma%20is%20a%20relatively,men%20and%2015%2C370%20in%20women . Accessed November 2024 . 11 SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/explorer/ . Accessed November 2024 . 12 American Cancer Society. What is Multiple Myeloma? https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html . Accessed November 2024 . 13 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html . Accessed November 2024 . Media contacts: Sarah Freeman sfreem21@its.jnj.com Christie Corbett ccorbet6@its.jnj.com Investor contact: Lauren Johnson investor-relations@its.jnj.com U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: https://www.prnewswire.com/news-releases/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-302325575.html SOURCE Johnson & Johnson

If you're busy operating a business or establishing a side hustle, shopping for groceries and managing household needs with trips across town can be challenging. Fortunately, Costco Gold Star Members can access a far-ranging selection of supplies under one roof and beyond. During Cyber Week, you can get a Costco 1-Year Gold Star Membership plus a $40 Digital Costco Shop Card* for only $65 and start shopping smarter. Stretch your budget by exploring the advantages of a Gold Star Membership, which features an additional Household Card that can be used by one adult member of your household that can be used on favorite products at any location. Offering access to more than 500 warehouses nationwide, Costco is an ideal destination for those looking to dominate their to-do list. Buy smarter with bulk goods and discover new value from brand names. Stock your kitchen, find quality everyday items , and see what's new in electronic devices and furniture, all while possibly getting a car tire installed. That experience awaits with a Costco Gold Star Membership. The impact extends beyond store aisles, as a Gold Star Membership comes complete with access to Costco Travel for exclusive vacation opportunities, along with Costco Optical and Costco Pharmacy at select locations. Plus, enjoy members-only savings on fuel when you refill your vehicle's tank at a Costco Gas Station before heading home. You can even use your perks when ordering online at Costco.com. It's easy to start using your Costco Gold Star Membership right away. Just purchase your membership here and provide a valid email address. Within two weeks of redeeming your membership purchase, you'll receive your $45 Digital Costco Shop Card* via email. Use it at a Costco location nearby or shop online. Keep in mind that this offer is only available for new members or those who had their membership expired more than 18 months ago. Gain greater value on a variety of household needs and much more by grabbing this Cyber Week deal: purchase a Costco 1-Year Gold Star Membership with a $40 Digital Costco Shop Card* for only $65 while supplies last. This offer ends tomorrow, December 8, at 11:59 p.m. PT. StackSocial prices subject to change. *Services are provided to Costco members by third parties.

The Conference of United Opposition Political Parties in Nigeria (CUOPPIN) has made a clarification on the ongoing report of protest notification against the management of NYSC, which the organisation allegedly made in an earlier statement. Reacting to the matter, Convener of the coalition, Comrade Dalapo Ibrahim, acknowledged that the said protest notification and the entirety of the allegations were made in error as all the issues raised where long dealt with under the previous two Director-Generals long before the assumption of duty by the current Director General, Brig Gen YD Ahmed. While referring to Gen. Ahmed as a shining star not just for the NYSC but for the military, he regretted the error and assured the scheme of the organisation’s unwavering support. Comrade Dalapo Ibrahim further explained that the protest notification was an error that was not authorised, neither was it in consideration at any point in time and urged the public to disregard same. “I must put it on record that the the current Director General, Brig Gen YD Ahmed was not yet appointed when all those petitions where received by our organisation. “Even at that, the allegations were investigated and confirmed to be unsubstantiated at the time it came up long before assumption of duty by the current DG. So, we must apologise to the management of the National Youth Service Corps (NYSC) for the inconveniences caused by the error. “It is worthy of note that within a short time in office, the Director General has bonded with the team he met on ground which has enabled him to adapt and sustain the reforms in the scheme . This must be commended. “Truth be told, never have we had a visionary leader at the NYSC that has fearlessly defended the integrity of the scheme like Brig Gen Ahmed YD Ahmed. “He is passionate and committed to the ideals of the scheme as envisioned by the founding fathers. Above all, he is openly committed to the vision of the scheme,” he said. The statement noted that the tempo in the skills acquisition drive of the Scheme under the current management is a demonstration of president Bola Ahmed Tinubu’s commitment to instilling a self sustainable culture amongst our youth to reduce over reliance on goverment jobs”The NYSC leads in this drive” “On the issue of the allowances of Corp members, it is important to give due credit to the current team at the NYSC for the push that gave birth to an increase in the allowances of Corp members ” It is no longer news that the government has since approved an upward review of corp members’ allowances in line with realities” Our findings indicate that the management has successfully achieved that push because of it’s commitment to welfare of Corp members ” Till this day, our Corp members are now leading in various areas in farming, ICT, small and medium scale enterprises across the public and private sectors etc. Accordingly, by this statement, the general public is urged to disregard the notification and the report in its entirety as the National Youth Service Corps under the current management is in safe hands.Dave & Buster’s expects to open its first Killeen location in the summer of 2025 according to a spokesperson for the company. The new entertainment and restaurant center will have more than 100 arcade games, innovative drinks and a chef-crafted food menu according to the spokesperson. It will also include a massive 40-feet high-definition TV designed to offer an unrivaled viewing experience at its state-of-the-art sports bar. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

WASHINGTON — For someone who has made winning a key part of his personal, professional and political brand, Donald Trump is set to rely on a large stable of losers in his second term. The president-elect has tapped more than a dozen people who previously lost elections to join his administration next year. Even though both parties love to deride unsuccessful candidates who run again, the term “loser” doesn’t have to be a pejorative. Losing candidates regularly get elected later, including in the 2014 and 2020 election cycles. It also isn’t a disqualifying factor to serve a president, or even to serve as president. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Scott Frost has telling quote about leaving UCF for Nebraska( MENAFN - GlobeNewsWire - Nasdaq) MONTREAL, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or“the Company”) announces some updates about the Company and takes this opportunity to thank its shareholders, partners and suppliers for their trust throughout 2024 and wishes them a Merry Christmas and a Happy New Year 2025. Mirabelli and Maqua Results The Company announces that it has received all its results related to the summer and fall 2024 exploration campaigns on the Mirabelli SM and Maqua SM properties. These do not reveal any significant grades in the metals and minerals initially sought. Management announces that exploration work will not be continued on these properties. The Company also announces that it no longer intends to continue exploration related to Lithium and will focus on the gold potential of its properties, in particular, the Amanda project now 100% owned and which contains numerous gold showings. Lichen and 113 North Projects Mosaic announces that it has received formal notification from Castlebar Capital Corporation that it is abandoning the option agreement to acquire 100% of the Lichen property (see press release dated June 11, 2024 ). Mosaic is regaining control of this property which consists of 282 claims covering a total area of ​​15,622 hectares and is located approximately 100 km west of the Chibougamau mining camp. The property is underlain by volcanic rocks of the Obatogamau Formation intersected by intermediate stocks and plutons. The volcanic belt parallels two known gold-bearing volcanic belts, the Bachelor Lake gold zone to the west and the Osisko-Windfall gold zone to the south. The Nelligan and Monster Lake gold projects are located at the eastern end of the volcanic belt. The Company also announces that it has received formal notification from Panther Minerals Inc. (formerly Lithium Lion Metals Inc.) that the latter is abandoning the option agreement to acquire 100% of the 113 North property (see press release dated December 5, 2023 ). Mosaic is regaining control of this property which is located in the southeastern part of the Abitibi Greenstone Belt and comprises 59 cells totaling 3,010 hectares within a 6- to 12-kilometre-wide band of volcano-sedimentary rocks located between the Josselin and Montgay granodiorite-tonalite batholiths. The volcanic rocks in this group have felsic, intermediate and mafic compositions and are cut by dunite, gabbro and diorite dykes. Iron formations (sulphides and oxides) and clastic sedimentary rocks, such as greywackes and schists, are also present. Gold, copper, nickel, platinum and palladium occurrences have been discovered in this geological environment near the project. The scientific and technical information of Mosaic Minerals Corporation included in this press release has been reviewed and approved by Gilles Laverdière, P.Geo, Vice-President Exploration of Mosaic Minerals and qualified person under National Instrument 43-101 respecting information concerning mining projects (“Regulation 43-101”). About Mosaic Minerals Corporation Mosaic Minerals Corp. is a Canadian mining exploration company listed on the Canadian Securities Exchange (CSE: MOC) focusing on the exploration of critical minerals such as Nickel in the province of Quebec. Source: M. Jonathan Hamel President & CEO ... This release contains certain“forward-looking information” under applicable Canadian securities laws concerning the Arrangement. Forward-looking information reflects the Company's current internal expectations or beliefs and is based on information currently available to the Company. In some cases, forward-looking information can be identified by terminology such as“may”,“will”,“should”,“expect”,“intend”,“plan”,“anticipate”,“believe”,“estimate”,“projects”,“potential”,“scheduled”,“forecast”,“budget” or the negative of those terms or other comparable terminology. Assumptions upon which such forward-looking information is based includes, among others, that the conditions to closing of the Arrangement will be satisfied and that the Arrangement will be completed on the terms set out in the definitive agreement. Many of these assumptions are based on factors and events that are not within the control of the Company, and there is no assurance they will prove to be correct or accurate. Risk factors that could cause actual results to differ materially from those predicted herein include, without limitation: that the remaining conditions to the Arrangement will not be satisfied; that the business prospects and opportunities of the Company will not proceed as anticipated; changes in the global prices for gold or certain other commodities (such as diesel, aluminum and electricity); changes in U.S. dollar and other currency exchange rates, interest rates or gold lease rates; risks arising from holding derivative instruments; the level of liquidity and capital resources; access to capital markets, financing and interest rates; mining tax regimes; ability to successfully integrate acquired assets; legislative, political or economic developments in the jurisdictions in which the Company carries on business; operating or technical difficulties in connection with mining or development activities; laws and regulations governing the protection of the environment; employee relations; availability and increasing costs associated with mining inputs and labour; the speculative nature of exploration and development; contests over title to properties, particularly title to undeveloped properties; and the risks involved in the exploration, development and mining business. Risks and unknowns inherent in all projects include the inaccuracy of estimated reserves and resources, metallurgical recoveries, capital and operating costs of such projects, and the future prices for the relevant minerals. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION IN THE UNITED STATES OR ANY US NEWS WIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE TITLES DESCRIBED HEREIN. MENAFN24122024004107003653ID1109028413 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Tottenham succumbed to a disappointing 4-3 defeat at their home ground against London rivals, Chelsea , despite taking a two-goal advantage 11 minutes into the clash. The Athletic jouranlist, Colin Millar has taken to social media to express his concerns about the side's, and specifically the manager's, inability to adapt based on game situations. There have been numerous occasions just this term in which Spurs have taken leads and lost them due to poor game management, including the 3-2 loss to Brighton earlier this season, and the draws to Roma and Fulham more recently. In addition, several worrying defeats to the likes of Ipswich Town and Bournemouth have further worried supporters, who are beginning to grow frustrated with a lack of consistency. Millar: Postecoglou Has a 'Serious Flaw' Speaking to X (formerly Twitter), Millar shared an "extraordinary" statistic, detailing that Spurs had lost a total of 19 games in 40 Premier League matches, citing stubbornness as a key reason. In fact, the last time the two London-based outfits met at this stadium, it was no short of an absolute mess. Despite incurring two red cards, Postecoglou remained adamant with his desired style of play, maintaning a high line with just nine men against the Chelsea attack. The game unsurprisingly ended 4-1 to Chelsea, and the Greek-Australian custodian's adventurous approach was subject to controversy, with many noting that such obstinance may be costly going forward. Indeed, in the same fixture this season, it was some similar adamance which inevitably saw Tottenham lose out on a vital three points. Despite sustaining a two-goal lead very early on, Spurs were unable to control the game, and allowed Chelsea numerous opportunities to turn the game around. Ange Postecoglou's Managerial Record at Tottenham Matches 63 Wins 32 Draws 9 Losses 22 Points per match 1.67 Firm questions are now being asked of Postecoglou's position as manager, as this repeated theme is still yet to be addressed. Pundit, Jamie O'Hara has already gone as far as to call for the sacking of the Tottenham boss , and if such performances continue, other supporters are likely to continue piling on the pressure from the outside. Fans are growing increasingly frustrated of Tottenham's abysmal lack of control of matches. Statistics courtesy of Transfermarkt.com - Correct as of 08/12/2024

A young TikToker learning to live with long COVID educates about chronic illness

None

SANTA CLARA, Calif. — Building the current crop of artificial intelligence chatbots has relied on specialized computer chips pioneered by Nvidia, which dominates the market and made itself the poster child of the AI boom. But the same qualities that make those graphics processor chips, or GPUs, so effective at creating powerful AI systems from scratch make them less efficient at putting AI products to work. That’s opened up the AI chip industry to rivals who think they can compete with Nvidia in selling so-called AI inference chips that are more attuned to the day-to-day running of AI tools and designed to reduce some of the huge computing costs of generative AI. “These companies are seeing opportunity for that kind of specialized hardware,” said Jacob Feldgoise, an analyst at Georgetown University’s Center for Security and Emerging Technology. “The broader the adoption of these models, the more compute will be needed for inference and the more demand there will be for inference chips.” It takes a lot of computing power to make an AI chatbot. It starts with a process called training or pretraining — the “P” in ChatGPT — that involves AI systems “learning” from the patterns of huge troves of data. GPUs are good at doing that work because they can run many calculations at a time on a network of devices in communication with each other. However, once trained, a generative AI tool still needs chips to do the work — such as when you ask a chatbot to compose a document or generate an image. That’s where inferencing comes in. A trained AI model must take in new information and make inferences from what it already knows to produce a response. GPUs can do that work, too. But it can be a bit like using a sledgehammer to crack a nut. “With training, you’re doing a lot heavier, a lot more work. With inferencing, that’s a lighter weight,” said Forrester analyst Alvin Nguyen. That’s led startups like Cerebras, Groq and d-Matrix as well as Nvidia’s traditional chipmaking rivals — such as AMD and Intel — to pitch more inference-friendly chips as Nvidia focuses on meeting the huge demand from bigger tech companies for its higher-end hardware. D-Matrix was founded in 2019 — a bit late to the AI chip game, as CEO Sid Sheth explained during a recent interview at the company’s headquarters in Santa Clara, California, the same Silicon Valley city that’s also home to AMD, Intel and Nvidia. “There were already 100-plus companies. So when we went out there, the first reaction we got was ‘you’re too late,’” he said. The pandemic’s arrival six months later didn’t help as the tech industry pivoted to focus on software to serve remote work. Now, however, Sheth sees a big market in AI inferencing, comparing that later stage of machine learning to how human beings apply the knowledge they acquired in school. “We spent the first 20 years of our lives going to school, educating ourselves. That’s training, right?” he said. “And then the next 40 years of your life, you kind of go out there and apply that knowledge — and then you get rewarded for being efficient.” The product, called Corsair, consists of two chips with four chiplets each, made by Taiwan Semiconductor Manufacturing Co. — the same manufacturer of most of Nvidia’s chips — and packaged together in a way that helps to keep them cool. The chips are designed in Santa Clara, assembled in Taiwan and then tested back in California. Testing is a long process and can take six months — if anything is off, it can be sent back to Taiwan. D-Matrix workers were doing final testing on the chips during a recent visit to a laboratory with blue metal desks covered with cables, motherboards and computers, with a cold server room next door. While tech giants like Amazon, Google, Meta and Microsoft have been gobbling up the supply of costly GPUs in a race to outdo each other in AI development, makers of AI inference chips are aiming for a broader clientele. Forrester’s Nguyen said that could include Fortune 500 companies that want to make use of new generative AI technology without having to build their own AI infrastructure. Sheth said he expects a strong interest in AI video generation. “The dream of AI for a lot of these enterprise companies is you can use your own enterprise data,” Nguyen said. “Buying (AI inference chips) should be cheaper than buying the ultimate GPUs from Nvidia and others. But I think there’s going to be a learning curve in terms of integrating it.” Feldgoise said that, unlike training-focused chips, AI inference work prioritizes how fast a person will get a chatbot’s response. He said another whole set of companies is developing AI hardware for inference that can run not just in big data centers but locally on desktop computers, laptops and phones. Better-designed chips could bring down the huge costs of running AI to businesses. That could also affect the environmental and energy costs for everyone else. Sheth says the big concern right now is, “are we going to burn the planet down in our quest for what people call AGI — human-like intelligence?” It’s still fuzzy when AI might get to the point of artificial general intelligence — predictions range from a few years to decades. But, Sheth notes, only a handful of tech giants are on that quest. “But then what about the rest?” he said. “They cannot be put on the same path.” Get local news delivered to your inbox!2 cheap dividend stocks to kickstart your 2025 portfolio - Finbold - Finance in BoldUS could 'absolutely' leave NATO, Trump says

Sebastian Zapeta, 33, who federal immigration officials said is a Guatemalan citizen who entered the US illegally, was arraigned in Brooklyn criminal court. He appeared briefly before a judge and wore a white jumpsuit over a weathered black hooded sweatshirt. He did not speak. He will remain jailed ahead of his next court date on Friday. The apparently random attack occurred on Sunday morning on a stationary F train at the Coney Island station in Brooklyn. Police said on Tuesday that identification of the victim was still “pending at this time”. Authorities say Zapeta approached the woman, who was sitting motionless in the train car and may have been sleeping, and used a lighter to set her clothing on fire. The woman quickly became engulfed in flames, while the suspect then sat at a bench on the subway platform and watched, according to police. Video posted to social media appeared to show the woman standing inside the train ablaze as some people look on from the platform, and at least one officer walks by. NYPD chief of transit Joseph Gulotta said that several officers had responded to the fire and one stayed to keep the crime scene “the way it’s supposed to be” while the others went to get fire extinguishers and transit workers. They were eventually able to douse the fire, but “unfortunately, it was too late”, Police Commissioner Jessica Tisch said — the woman was pronounced dead at the scene. During Zapeta’s court hearing on Tuesday, Assistant District Attorney Ari Rottenberg said Zapeta at one point fanned the flames on the woman using his shirt. He said a 911 call from a subway rider helped identify Zapeta. Mr Rottenberg added that under interrogation Zapeta claimed he did not know what happened, noting that he consumes alcohol. But he alleged that Zapeta identified himself to interrogators in images related to the attack. Zapeta was taken into custody on Sunday afternoon while riding a train on the same subway line after police got a tip from some teenagers who recognised him from images circulated by the police. A Brooklyn address for Zapeta released by police matches a shelter that provides housing and substance abuse support. The shelter did not immediately respond to a request for comment. Federal immigration officials said Zapeta had been previously deported in 2018 but at some point reentered the US illegally. The crime — and the graphic video of it that ricocheted across social media — deepened a growing sense of unease among some New Yorkers about the safety of the subway system in a city where many residents take the subway multiple times each day.( MENAFN - GlobeNewsWire - Nasdaq) MONTREAL, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or“the Company”) announces some updates about the Company and takes this opportunity to thank its shareholders, partners and suppliers for their trust throughout 2024 and wishes them a Merry Christmas and a Happy New Year 2025. Mirabelli and Maqua Results The Company announces that it has received all its results related to the summer and fall 2024 exploration campaigns on the Mirabelli SM and Maqua SM properties. These do not reveal any significant grades in the metals and minerals initially sought. Management announces that exploration work will not be continued on these properties. The Company also announces that it no longer intends to continue exploration related to Lithium and will focus on the gold potential of its properties, in particular, the Amanda project now 100% owned and which contains numerous gold showings. Lichen and 113 North Projects Mosaic announces that it has received formal notification from Castlebar Capital Corporation that it is abandoning the option agreement to acquire 100% of the Lichen property (see press release dated June 11, 2024 ). Mosaic is regaining control of this property which consists of 282 claims covering a total area of ​​15,622 hectares and is located approximately 100 km west of the Chibougamau mining camp. The property is underlain by volcanic rocks of the Obatogamau Formation intersected by intermediate stocks and plutons. The volcanic belt parallels two known gold-bearing volcanic belts, the Bachelor Lake gold zone to the west and the Osisko-Windfall gold zone to the south. The Nelligan and Monster Lake gold projects are located at the eastern end of the volcanic belt. The Company also announces that it has received formal notification from Panther Minerals Inc. (formerly Lithium Lion Metals Inc.) that the latter is abandoning the option agreement to acquire 100% of the 113 North property (see press release dated December 5, 2023 ). Mosaic is regaining control of this property which is located in the southeastern part of the Abitibi Greenstone Belt and comprises 59 cells totaling 3,010 hectares within a 6- to 12-kilometre-wide band of volcano-sedimentary rocks located between the Josselin and Montgay granodiorite-tonalite batholiths. The volcanic rocks in this group have felsic, intermediate and mafic compositions and are cut by dunite, gabbro and diorite dykes. Iron formations (sulphides and oxides) and clastic sedimentary rocks, such as greywackes and schists, are also present. Gold, copper, nickel, platinum and palladium occurrences have been discovered in this geological environment near the project. The scientific and technical information of Mosaic Minerals Corporation included in this press release has been reviewed and approved by Gilles Laverdière, P.Geo, Vice-President Exploration of Mosaic Minerals and qualified person under National Instrument 43-101 respecting information concerning mining projects (“Regulation 43-101”). About Mosaic Minerals Corporation Mosaic Minerals Corp. is a Canadian mining exploration company listed on the Canadian Securities Exchange (CSE: MOC) focusing on the exploration of critical minerals such as Nickel in the province of Quebec. Source: M. Jonathan Hamel President & CEO ... This release contains certain“forward-looking information” under applicable Canadian securities laws concerning the Arrangement. Forward-looking information reflects the Company's current internal expectations or beliefs and is based on information currently available to the Company. In some cases, forward-looking information can be identified by terminology such as“may”,“will”,“should”,“expect”,“intend”,“plan”,“anticipate”,“believe”,“estimate”,“projects”,“potential”,“scheduled”,“forecast”,“budget” or the negative of those terms or other comparable terminology. Assumptions upon which such forward-looking information is based includes, among others, that the conditions to closing of the Arrangement will be satisfied and that the Arrangement will be completed on the terms set out in the definitive agreement. Many of these assumptions are based on factors and events that are not within the control of the Company, and there is no assurance they will prove to be correct or accurate. Risk factors that could cause actual results to differ materially from those predicted herein include, without limitation: that the remaining conditions to the Arrangement will not be satisfied; that the business prospects and opportunities of the Company will not proceed as anticipated; changes in the global prices for gold or certain other commodities (such as diesel, aluminum and electricity); changes in U.S. dollar and other currency exchange rates, interest rates or gold lease rates; risks arising from holding derivative instruments; the level of liquidity and capital resources; access to capital markets, financing and interest rates; mining tax regimes; ability to successfully integrate acquired assets; legislative, political or economic developments in the jurisdictions in which the Company carries on business; operating or technical difficulties in connection with mining or development activities; laws and regulations governing the protection of the environment; employee relations; availability and increasing costs associated with mining inputs and labour; the speculative nature of exploration and development; contests over title to properties, particularly title to undeveloped properties; and the risks involved in the exploration, development and mining business. Risks and unknowns inherent in all projects include the inaccuracy of estimated reserves and resources, metallurgical recoveries, capital and operating costs of such projects, and the future prices for the relevant minerals. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION IN THE UNITED STATES OR ANY US NEWS WIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE TITLES DESCRIBED HEREIN. MENAFN24122024004107003653ID1109028413 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.M3 Group Joins MEDIROM Mother Labs’ Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money ValuationThe Kharga Corps of the Indian Army concluded its integrated field firing exercise, ‘Kharga Shakti’, at the Mahajan Field Firing Ranges in Rajasthan. The exercise, which began on November 24, tested the Corps’ combat readiness and validated the effectiveness of combined arms operations in a simulated battlefield environment. Lieutenant General Rajesh Pushkar, General Officer Commanding (GOC) of the Kharga Corps, reviewed the exercise, which showcased coordinated maneuvers and integrated firing by various military assets. These included attack helicopters, artillery guns, armored and mechanized platforms, and infantry weapons. The troops demonstrated their operational capabilities through live firing drills, tactical movements, and air support missions. The exercise also incorporated cutting-edge technologies such as swarm drones, loiter munition systems, quadcopters, and logistic drones to enhance battlefield efficiency. During his visit, Lt Gen Pushkar interacted with the troops, commending their exceptional professionalism and combat skills. He reaffirmed the armed forces’ commitment to maintaining a high state of readiness and operational excellence, expressing confidence in the Kharga Corps’ ability to be a decisive force on the Western Front. The ‘Kharga Shakti’ exercise underscores the Indian Army’s focus on modern warfare techniques and its dedication to achieve the highest standards of combat preparedness, Lt Gen Pushkar said.